mergers & acquisitions
Predictive Oncology Acquires 3D Tumor Model Developer ZPredicta
Predictive Oncology will integrate information from ZPredicta's 3D tumor models into its AI-based platforms and inform precision drug development.
Blueprint Medicines Acquires Lengo Therapeutics in $465M Deal
The acquisition adds Lengo's EGFR inhibitor LNG-451 to Blueprint's pipeline, which already includes two other investigational EGFR inhibitors.
Cancer Dx Firms ACT Genomics, Sanomics Merge
The companies will offer tissue and liquid-based tests for cancer, using technologies such as next-generation sequencing, digital PCR, and gene chips.
ConcertAI, TeraRecon Merge to Bolster Real-World Data Analytics for Precision Oncology Research
The joining of the two SymphonyAI companies will improve life sciences organizations' ability to visualize and interpret imaging data alongside genomic and clinical information.
Illumina Acquires Grail Despite Ongoing Regulatory Scrutiny
Illumina said it will hold Grail as a separate company during the European Commission's ongoing regulatory review and abide by the outcome of the FTC's administrative trial.